• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    2/10/25 10:25:37 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Prothena Corporation Public Limited Company

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    G72800108

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G72800108


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,094,682.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,130,876.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,130,876.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G72800108


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,094,682.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,130,876.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,130,876.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G72800108


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,094,682.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,130,876.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,130,876.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G72800108


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,090,828.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,090,828.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,130,876.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Prothena Corporation Public Limited Company
    (b)Address of issuer's principal executive offices:

    77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2 D02 VK60
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    G72800108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    9.54  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Vanguard Health Care Fund
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:02/10/2025
    Get the next $PRTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    5/27/2025Outperform → Perform
    Oppenheimer
    5/27/2025$6.00Buy → Hold
    Jefferies
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    More analyst ratings

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

    2/12/26 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Announces Board of Directors Update

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. "I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and lea

    12/12/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

    TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena's CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways Systemically-administered TDP-43 CYTOPE rapidly and efficiently distributed to the brain and periphery, internalized into the cytosol and significantly reduced intracellular TDP-43 pathology in an ALS mouse model TDP-43 CYTOPE meaningfully reduced intracellular TDP-43 pathology and associated RNA dysregulation caused by cryptic exon inclusions - key pathogenic features of TDP-43 proteinopathies - in a human-derived neuronal cell line   Prothena Corporation plc (NASDAQ

    11/19/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    5/2/25 10:29:05 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Zago Wagner M. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Walker Karin L was granted 25,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:14 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Swanson Chad J. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:01 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    SEC Filings

    View All

    Prothena Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    12/12/25 4:26:08 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    11/19/25 4:30:57 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/12/25 3:47:28 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prothena downgraded by BofA Securities with a new price target

    BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00

    5/28/25 8:10:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Oppenheimer

    Oppenheimer downgraded Prothena from Outperform to Perform

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Jefferies with a new price target

    Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Financials

    Live finance-specific insights

    View All

    Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

    2/12/26 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report Third Quarter 2025 Financial Results on November 6

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on November 6. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the p

    10/30/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    View All

    Prothena Announces Board of Directors Update

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. "I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and lea

    12/12/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

    11/12/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports First Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

    5/8/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/14/24 1:22:34 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 7:00:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 6:06:27 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care